Abstract
Gastric cancer (GC) is common in the northeast and southern parts of India. Radical surgery is the cornerstone of treatment and offers the only chance for cure. This study was conducted to assess the outcomes of all resectable gastric cancers that presented to our tertiary cancer center in Northeast India. All patients undergoing upfront surgery for gastric cancer with curative intention between 2012 and 2017 were included in the study. A total of 116 patients who underwent upfront radical gastrectomy were included in the study. Males (58.6%) were more common than females (41.4%). Mean age at presentation was 56.12 years (range 26–89). The most common mode of presentation was pain abdomen (53.8%). The most common location of tumor was the distal part (81%) followed by the proximal part (10.3%). The most commonly done procedure was distal radical gastrectomy (56.9%) followed by subtotal gastrectomy (32.8%). Median number of lymph nodes isolated was 14. Fifty-four patients received adjuvant chemotherapy while 32 patients received adjuvant chemoradiation (CTRT). At a median follow-up of 14 months (range, 2–78 months), overall 5-year survival was 23.75% (mean survival 33.77 months, median survival 24 months). The 5-year survival for stages I–III was 100%, 26.25%, and 11.25%, respectively (P < 0.001). Though perioperative chemotherapy has a role in gastric cancer, it is not the substitute for radical D2 gastrectomy which is still the gold standard treatment especially in high-volume centers.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA Cancer J Clin 68(1):7–30
Dikshit RP, Mathur G, Mhatre S, Yeole BB (2011) Epidemiological review of gastric cancer in India. Indian J Med Paediatr Oncol 32:3–11
Sharma A, Radhakrishnan V (2011) Gastric cancer in India. Indian J Med Paediatr Oncol 32:12–16
GLOBOCAN Cancer fact sheets: stomach cancers [Internet]. Available from: http://globocan.iarc.fr/old/FactSheets/cancers/stomach-new.asp.
Cunningham D, Allum WH, Stenning SP, Thompson JN, van de Velde C, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ, MAGIC Trial Participants (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20
Shrikhande SV, Barreto SG, Talole SD et al. (2013) “D2 lymphadenectomy is not only safe but necessary in the era of neoadjuvant chemotherapy,” World J Surg Oncol, vol. 11, article no. 31
Weledji EP, Verla V (2016) Failure to rescue patients from early critical complications of oesophagogastric cancer surgery. Ann Med Surg (Lond) 2:34–41
Vasilescu C, Herlea V, Tidor S, Ivanov B, Stănciulea O, Mănuc M, Gheorghe C, Ionescu M, Diculescu M, Popescu I (2006) D2 lymph node dissection in gastric cancer surgery: long term results—analysis of an experience with 227 patients. Chirurgia (Bucur) 101:375–384
Cho BC, Jeung HC, Choi HJ, Rha SY, Hyung WJ, Cheong JH, Noh SH, Chung HC (2007) Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: a 15-year experience at a single institute. J Surg Oncol 95:461–468
Songun I, Putter H, Kranenbarg EMK, Sasako M, van de Velde CJ (2010) Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol 11:439–449
Shrikhande SV, Barreto SG, Talole SD, Vinchurkar K, Annaiah S, Suradkar K et al (2013) D2 lymphadenectomy is not only safe but necessary in the era of neoadjuvant chemotherapy. World J Surg Oncol 2:11–31
Shrikhande SV, Shukla PJ, Qureshi S, Siddachari R, Upasani V, Ramadwar M, Kakade AC, Hawaldar R (2006) D2 lymphadenectomy for gastric cancer in Tata Memorial Hospital: Indian data can now be incorporated in future international trials. Dig Surg 23:192–197
Rajdev L (2010) Treatment options for surgically resectable gastric cancer. Curr Treat Options in Oncol 11:14–23
Sano T (2008) Adjuvant and neoadjuvant therapy of gastric cancer: a comparison of three pivotal studies. Curr Oncol Rep 10:191–198
Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Gennari L, Italian Gastrointestinal Tumor Study Group (1999) Subtotal versus total gastrectomy for gastric cancer: five-year survival rates in a multicenter randomized Italian trial. Ann Surg 230(2):170–178. https://doi.org/10.1097/00000658-199908000-00006
Bonenkamp JJ, Hermans J, Sasako M et al (1999) Extended lymph-node dissection for gastric cancer. N Engl J Med 340(12):908–914. https://doi.org/10.1056/NEJM199903253401202
Ychou M, Boige V, Pignon JP, Conroy T, Bouché O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Genève J, Lasser P, Rougier P (2011) Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 29:1715–1721
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Purkayastha, J., Yadav, J., Talukdar, A. et al. Radical Gastrectomy: Still the Gold Standard Treatment for Gastric Cancer—Our Experience from a Tertiary Care Center from Northeast India. Indian J Surg Oncol 11, 66–70 (2020). https://doi.org/10.1007/s13193-019-00990-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13193-019-00990-x